130 related articles for article (PubMed ID: 38810787)
1. At-home, telehealth-supported ketamine treatment for depression: Findings from longitudinal, machine learning and symptom network analysis of real-world data.
Mathai DS; Hull TD; Vando L; Malgaroli M
J Affect Disord; 2024 May; 361():198-208. PubMed ID: 38810787
[TBL] [Abstract][Full Text] [Related]
2. At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial.
Hull TD; Malgaroli M; Gazzaley A; Akiki TJ; Madan A; Vando L; Arden K; Swain J; Klotz M; Paleos C
J Affect Disord; 2022 Oct; 314():59-67. PubMed ID: 35809678
[TBL] [Abstract][Full Text] [Related]
3. Letter to the Editor: CONVERGENCES AND DIVERGENCES IN THE ICD-11 VS. DSM-5 CLASSIFICATION OF MOOD DISORDERS.
Cerbo AD
Turk Psikiyatri Derg; 2021; 32(4):293-295. PubMed ID: 34964106
[TBL] [Abstract][Full Text] [Related]
4. Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Dean RL; Hurducas C; Hawton K; Spyridi S; Cowen PJ; Hollingsworth S; Marquardt T; Barnes A; Smith R; McShane R; Turner EH; Cipriani A
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD011612. PubMed ID: 34510411
[TBL] [Abstract][Full Text] [Related]
5. Ketamine and other glutamate receptor modulators for depression in adults.
Caddy C; Amit BH; McCloud TL; Rendell JM; Furukawa TA; McShane R; Hawton K; Cipriani A
Cochrane Database Syst Rev; 2015 Sep; (9):CD011612. PubMed ID: 26395901
[TBL] [Abstract][Full Text] [Related]
6. A Cohort-Based Case Report: The Impact of Ketamine-Assisted Therapy Embedded in a Community of Practice Framework for Healthcare Providers With PTSD and Depression.
Dames S; Kryskow P; Watler C
Front Psychiatry; 2021; 12():803279. PubMed ID: 35095617
[TBL] [Abstract][Full Text] [Related]
7. Real-world depression, anxiety and safety outcomes of intramuscular ketamine treatment: a retrospective descriptive cohort study.
Ahuja S; Brendle M; Smart L; Moore C; Thielking P; Robison R
BMC Psychiatry; 2022 Oct; 22(1):634. PubMed ID: 36192794
[TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcomes of Intravenous Ketamine Treatment for Depression in the VA Health System.
Pfeiffer PN; Geller J; Ganoczy D; Jagusch J; Carty J; Festin FED; Gilmer WS; Martis B; Ranganathan M; Wiechers IR; Hosanagar A
J Clin Psychiatry; 2024 Jan; 85(1):. PubMed ID: 38206011
[No Abstract] [Full Text] [Related]
10. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults.
McCloud TL; Caddy C; Jochim J; Rendell JM; Diamond PR; Shuttleworth C; Brett D; Amit BH; McShane R; Hamadi L; Hawton K; Cipriani A
Cochrane Database Syst Rev; 2015 Sep; (9):CD011611. PubMed ID: 26415966
[TBL] [Abstract][Full Text] [Related]
11. The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression.
Garel N; Drury J; Thibault Lévesque J; Goyette N; Lehmann A; Looper K; Erritzoe D; Dames S; Turecki G; Rej S; Richard-Devantoy S; Greenway KT
Front Psychiatry; 2023; 14():1268832. PubMed ID: 37795512
[TBL] [Abstract][Full Text] [Related]
12. Anterior default mode network and posterior insular connectivity is predictive of depressive symptom reduction following serial ketamine infusion.
Wade BSC; Loureiro J; Sahib A; Kubicki A; Joshi SH; Hellemann G; Espinoza RT; Woods RP; Congdon E; Narr KL
Psychol Med; 2022 Sep; 52(12):2376-2386. PubMed ID: 35578581
[TBL] [Abstract][Full Text] [Related]
13. Association between peripheral biomarkers and clinical response to IV ketamine for unipolar treatment-resistant depression: An open label study.
Kang MJY; Vazquez GH
J Affect Disord; 2022 Dec; 318():331-337. PubMed ID: 36070831
[TBL] [Abstract][Full Text] [Related]
14. A qualitative and quantitative account of patient's experiences of ketamine and its antidepressant properties.
Sumner RL; Chacko E; McMillan R; Spriggs MJ; Anderson C; Chen J; French A; Jung S; Rajan A; Malpas G; Hay J; Ponton R; Muthukumaraswamy SD; Sundram F
J Psychopharmacol; 2021 Aug; 35(8):946-961. PubMed ID: 33781107
[TBL] [Abstract][Full Text] [Related]
15. Safety, effectiveness and tolerability of sublingual ketamine in depression and anxiety: A retrospective study of off-label, at-home use.
Hassan K; Struthers WM; Sankarabhotla A; Davis P
Front Psychiatry; 2022; 13():992624. PubMed ID: 36245861
[TBL] [Abstract][Full Text] [Related]
16. The Safety, Clinical, and Neurophysiological Effects of Intranasal Ketamine in Patients Who Do Not Respond to Electroconvulsive Therapy: Protocol for a Pilot, Open-Label Clinical Trial.
Knyahnytska Y; Zomorrodi R; Kaster T; Voineskos D; Trevizol A; Blumberger D
JMIR Res Protoc; 2022 Jan; 11(1):e30163. PubMed ID: 34882570
[TBL] [Abstract][Full Text] [Related]
17. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Diazgranados N; Ibrahim L; Brutsche NE; Newberg A; Kronstein P; Khalife S; Kammerer WA; Quezado Z; Luckenbaugh DA; Salvadore G; Machado-Vieira R; Manji HK; Zarate CA
Arch Gen Psychiatry; 2010 Aug; 67(8):793-802. PubMed ID: 20679587
[TBL] [Abstract][Full Text] [Related]
18. Predicting non-response to ketamine for depression: An exploratory symptom-level analysis of real-world data among military veterans.
Miller EA; Afshar HT; Mishra J; McIntyre RS; Ramanathan D
Psychiatry Res; 2024 May; 335():115858. PubMed ID: 38547599
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported outcomes on sleep quality and circadian rhythm during treatment with intravenous ketamine for treatment-resistant depression.
Yan R; Marshall T; Khullar A; Nagle T; Knowles J; Malkin M; Chubbs B; Swainson J
Ther Adv Psychopharmacol; 2024; 14():20451253241231264. PubMed ID: 38440104
[TBL] [Abstract][Full Text] [Related]
20. Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.
Dean RL; Marquardt T; Hurducas C; Spyridi S; Barnes A; Smith R; Cowen PJ; McShane R; Hawton K; Malhi GS; Geddes J; Cipriani A
Cochrane Database Syst Rev; 2021 Oct; 10(10):CD011611. PubMed ID: 34623633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
